(Press-News.org) CINCINNATI – Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).
Scientists from Cincinnati Children's Hospital Medical Center report their findings online Dec. 10 in the Journal of Clinical Investigation.
"We can for the first time shrink the large majority of neurofibromas, at least in mice, by using a molecularly targeted treatment," said Nancy Ratner, PhD, principal investigator and program leader for the Cancer Biology and Neural Tumors Program in the Cancer and Blood Disorders Institute at Cincinnati Children's. "At present there is no treatment for these tumors and our data provide strong rationale for testing this therapy in clinical trials for NF1."
Neurofibromas are benign tumors that grow along peripheral nerves in the body. They affect up to half of the people who have NF1. In the United States alone there are 10,000 people with NF1. Fueled initially by mutation of the tumor-suppressing gene NF1, the tumors can grow to become quite large and compress vital organs. They can also transform into deadly malignant peripheral nerve sheath tumors (MPNSTs), the leading cause of death in people with NF1.
The researchers tested an existing experimental drug from Pfizer called PD0325901, which in the current study shrank NF1 tumors in over 80 percent of the mice treated. Study authors report it was "the most dramatic result described to date for neurofibroma bearing mice."
The drug inhibits a protein called MEK, part of a molecular signaling chain that relays genetic instructions to the cell nucleus to promote cell growth. Researchers decided to test the drug after conducting a cross-species bioinformatics computer analysis of mouse and human NF1 tumors. The analysis identified genes and molecules that regulate cell signals driving the growth of neurofibromas and MPNSTs in both species.
The drug is currently being tested in human clinical trials for cancers that involve molecular components similar to those in NF1, in particular the MEK protein.
MEK is a downstream molecular target for a group of cell signaling proteins called Ras-GTPase. The proteins work together in a molecular relay to activate normal cell growth. In the instance of genetic mutation, Ras-GTPase can get stuck in the "on" position and promote hyperactive cell growth, tumor formation or cancer. Overactive Ras-GTPase signaling has been linked to a number of cancers.
In the case of mouse and human NF1 tumors, bioinformatics computer analysis suggested that deregulated Ras-GTPase signaling prompted MEK to stimulate the sustained activity of an enzyme called ERK. To confirm whether this molecular pathway is critical to NF1 tumor growth, researchers tested the MEK-blocking drug in genetically engineered mice.
The mice lacked expression of the NF1 gene and its tumor suppressing protein, causing the animals to develop benign neurofibromas. Scientists also transplanted human malignant peripheral nerve sheath tumor cells into a separate group of genetically receptive mice, which developed their own cancerous tumors.
Researchers then tested different doses of the drug to identify an optimal dose – one that would achieve the maximum amount of tumor shrinking efficiency with the least amount of toxicity. Treatment with PD0325901 reduced the abnormal growth of cells in both benign neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs). It also reduced the volume of tumor feeding blood vessels.
Treated mice with benign neurofibromas had significant shrinkage of their tumors after 60 days, compared to untreated mice. In mice implanted with human MPNSTs, the drug diminished cancerous tumor growth and doubled survival time to 52 days, as compared to untreated animals.
Researchers said overall shrinkage of MPNSTs was modest compared to that achieved in benign tumors, possibly because additional molecular pathways are involved in their formation. They said this suggests that MPNSTs may require a combinatory treatment that includes PD0325901 in conjunction with other therapies.
Mutations of the NF1 gene are frequently found in other cancers, such as glioblastoma, lung adenocarcinoma and ovarian cancer. The researchers said this could open the possibility of studying the Ras-MEK-ERK pathway as molecular target for treating these diseases.
### Funding for the study came from: the DAMD Program on Neurofibromatosis for the NF1 Microarray Consortium (DODW81XWH-09-1-0135 and W81XWH-04-1-0273); the Children's Tumor Foundation for support to the NF1 Preclinical Consortium; a National Institutes of Health Bench to Bedside Award for MRI Analyses (NIH-P50-NS05753) and an American Recovery and Reinvestment Act supplement to NIH grant R01-NS28840. The drug was provided by the manufacturer, Pfizer Inc.
About Cincinnati Children's:
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2012 Best Children's Hospitals ranking. It is ranked #1 for neonatology and in the top 10 for all pediatric specialties. Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health and a research affiliate of the University of Cincinnati College of Medicine. It is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org.
Study identifies targeted molecular therapy for untreatable NF1 tumors
2012-12-10
ELSE PRESS RELEASES FROM THIS DATE:
Bed bugs are not repelled by commercial ultrasonic frequency devices
2012-12-10
Alternative means of controlling urban insect pests by using ultrasonic frequencies are available and marketed to the public. However, few of these devices have been demonstrated as being effective in repelling insect pests such as mosquitoes, cockroaches, or ants. Despite the lack of evidence for the efficacy of such devices, they continue to be sold and new versions targeting bed bugs are readily available.
However, according to a soon-to-be-published article in the Journal of Economic Entomology, commercial devices that produce ultrasound frequencies are NOT promising ...
Depression in elderly men linked to higher rates of emergency admissions
2012-12-10
Depressed elderly men have a twofold risk of admission to hospital, found a new study published in CMAJ (Canadian Medical Association Journal). This finding could have potential for helping identify at-risk men to prevent admissions.
"Men with depression had a twofold increase in the mean number of hospital admissions, and these lasted on average twice as long as for men without depression," writes Dr. Matthew Prina, Institute of Public Health, Cambridge University, Cambridge, UK, with coauthors.
Researchers from Australia, the UK and the Netherlands undertook a study ...
From fish to man: Research reveals how fins became legs
2012-12-10
Vertebrates' transition to living on land, instead of only in water, represented a major event in the history of life. Now, researchers reporting in the December issue of the Cell Press journal Developmental Cell provide new evidence that the development of hands and feet occurred through the gain of new DNA elements that activate particular genes.
"First, and foremost, this finding helps us to understand the power that the modification of gene expression has on shaping our bodies," says Dr. José Luis Gómez-Skarmeta of the CSIC-Universidad Pablo de Olavide-Junta de Andalucía, ...
(Antibody) orientation matters
2012-12-10
The orientation of antibody binding to bacteria can mean life or death to the bug, according to a study published in The Journal of Experimental Medicine on December 10th. These findings may help explain why these bacteria cause millions of localized infections, but more serious, systemic blood infections are rare.
Streptococcus pyogenes—the causative agent of strep throat—typically invades the body's mucosal surfaces, including the throat and skin. These invasions are kept in check by Y-shaped immune proteins called antibodies, which attach to the bug via their arm ...
To fight incurable metastatic breast cancer, resistance must be broken
2012-12-10
One of the most frustrating truths about cancer is that even when a treatment works, it often doesn’t work for long because cancer cells find ways to resist. However, researchers reporting studies done in mice in the December 11, 2012, issue of Cancer Cell, a Cell Press publication, may have a way to stay one step ahead in the case of aggressive metastatic breast cancer.
The findings emphasize the importance of basic cancer biology for advancing treatments that are more effective and less toxic, the researchers say.
"We need to gain a better understanding of the wiring ...
Into adulthood, sickle cell patients rely on ER
2012-12-10
Patients with sickle cell disease rely more on the emergency room as they move from pediatric to adult health care, according to researchers at Washington University School of Medicine in St. Louis.
An analysis of Medicaid data of more than 3,200 patients with sickle cell disease shows that emergency room visits tripled from age 15 to age 24. The research is reported Dec. 10 at the American Society of Hematology's annual meeting, in Atlanta.
"There seems to be a breakdown in medical care during the transition from childhood to adulthood," says hematologist Morey A. ...
New studies reveal critical insights to improve care of patients with sickle cell disease
2012-12-10
(ATLANTA, December 10, 2012) – Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH).
Sickle cell disease (SCD) is an inherited, chronic blood disorder affecting between 90,000 and 100,000 Americans. Instead of producing healthy red blood cells, individuals with the disease produce abnormal, sickle-shaped cells that cannot easily move through blood vessels and deliver adequate oxygen to the body's tissues ...
Joslin scientists: Brown adipose tissue beneficial for metabolism and glucose tolerance
2012-12-10
BOSTON – December 10, 2012 – Joslin Diabetes Center scientists have demonstrated that brown adipose tissue (BAT) has beneficial effects on glucose tolerance, body weight and metabolism. The findings, which may lead to new treatments for diabetes, appear in the upcoming issue of the Journal of Clinical Investigation.
Unlike the more prevalent white adipose tissue (WAT or white fat) which stores fat, BAT (or brown fat) burns fat to produce heat. Studies in mice and humans have suggested that BAT also plays a role in regulating body weight and metabolism. This has made ...
Elk bones tell stories of life, death, and habitat use at Yellowstone National Park
2012-12-10
Josh Miller likes to call himself a conservation paleobiologist. The label makes sense when he explains how he uses bones as up-to-last-season information on contemporary animal populations.
Bones, he says, provide baseline ecological data on animals complementary to aerial counts, adding a historical component to live observation. In his November cover article for the Ecological Society of America's journal Ecology, he assesses elk habitat use in Yellowstone National Park by their bones and antlers, testing his method against several decades of the Park Service's meticulous ...
New multiple myeloma drug shows promise in treating people with advanced disease
2012-12-10
A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.
A multi-center research team evaluated 113 patients with multiple myeloma who had received at least two prior therapies and had subsequent disease progression to determine safety and efficacy of ...